Nikhil C. Munshi MD
Adjunct Associate Professor, Hematology & Medical Oncology
72 E. Concord Street nikhil.munshi@va.gov
Sections
Hematology & Medical Oncology
Biography
Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.
A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.
Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.
Education
MD, Maharaja Sayajirao University
MBBS, Maharaja Sayajirao University
Publications
Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, Favasuli V, Liu N, Todoerti K, Chakraborty C, Yao Y, Fulciniti M, Samur M, Aktas-Samur A, Amodio N, Turi M, Barello F, Penailillo J, Giallongo C, Romano A, Gulla A, Anderson KC, Inghirami G, Munshi NC, Loda M. Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. Clin Cancer Res. 2025 May 15; 31(10):1975-1987. PMID: 40053701.
Published on 5/15/2025Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2025 May 15; 31(10):2063. PMID: 40370044.
Published on 5/2/2025Giorgetti G, Maroto-Martin E, Soncini D, Fenoglio D, Becherini P, Benzi A, Ravera S, Traverso I, Ladisa F, Lai F, Rivoli G, Truffelli D, Nahimana A, Cagnetta A, Guolo F, Uras CRM, Schavgoulidze A, Fong Ng J, Nencioni A, Bruzzone S, Munshi NC, Lemoli RM, Fulciniti M, Cea M. CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma. Blood Cancer J. 2025 May 02; 15(1):83. PMID: 40316562.
Published on 4/29/2025Perini T, Zordan P, Del Pizzo R, Resnati M, Viviani L, Stefanoni D, Cassina L, Orfanelli UP, Trudu M, Oliva L, Lacidogna D, Samur MK, Materozzi M, Drago D, Andolfo A, Patrone M, Degano M, Boletta A, Milan E, Ciceri F, Munshi NC, Bellone M, Cenci S. The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma. Blood. 2025 Apr 29. PMID: 40300074.
Published on 4/23/2025Frenking JH, Zhou X, Rejeski K, Wagner V, Costello P, Hielscher T, Gatti L, Kauer J, Nadeem O, Mai EK, Michel CS, Friedrich MJ, Sedloev DN, Weinhold N, Goldschmidt H, Herfarth K, Schmitt A, Hundemer M, Schmitt M, Müller-Tidow C, Topp MS, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS. Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025 Apr 23. PMID: 40267180.
Published on 4/7/2025Paiva B, Shi Q, Puig N, Cedena MT, Orfao A, Durie BGM, Munshi NC, San-Miguel J. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025 Apr 07. PMID: 40195455.
Published on 3/16/2025Chakraborty C, Talluri S, Binder M, Morelli E, Mayoral JE, Derebail S, Aktas Samur A, Epstein CB, Anderson KC, Shammas MA, Samur MK, Fulciniti M, Munshi NC. Loss of BCL7A Permits IRF4 Transcriptional Activity and Cellular Growth in Multiple Myeloma. Blood. 2025 Mar 16. PMID: 40090008.
Published on 3/11/2025Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell T, Kaiser SM, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje NS. Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1132-1136. PMID: 39813623.
Published on 2/23/2025Nardone C, Gao J, Seo HS, Mintseris J, Ort L, Yip MCJ, Negasi M, Besschetnova AK, Kamitaki N, Gygi SP, Dhe-Paganon S, Munshi N, Fulciniti M, Greenberg ME, Shao S, Elledge SJ, Gu X. Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. bioRxiv. 2025 Feb 23. PMID: 40027645.
Published on 2/20/2025Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy C, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth N, Sakrikar D, Perkins M, Harding S, Troske D, Getz G, Karlson EW, Munshi N, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM. Serum free light chains in a racially diverse population including African Americans and populations from South Africa. Blood. 2025 Feb 20; 145(8):840-849. PMID: 39571144.